A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
Novartis
Novartis
Children's Oncology Group
Astellas Pharma Inc
St. Jude Children's Research Hospital
Baylor College of Medicine
Delta-Fly Pharma, Inc.
St. Jude Children's Research Hospital
Astellas Pharma Inc
City of Hope Medical Center
National Cancer Institute (NCI)
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Baylor College of Medicine
Sanofi
Children's Oncology Group
City of Hope Medical Center
City of Hope Medical Center
City of Hope Medical Center
Thomas Jefferson University
Servier
University of Pittsburgh
Children's Hospital of Soochow University
Arog Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
Ohio State University Comprehensive Cancer Center
Cornerstone Pharmaceuticals
Zhejiang University
University of Florida
Emory University
Roswell Park Cancer Institute
St. Jude Children's Research Hospital
Children's Oncology Group
Fred Hutchinson Cancer Center
University of Ulm
National Cancer Institute (NCI)
Massachusetts General Hospital
Medical College of Wisconsin
Therapeutic Advances in Childhood Leukemia Consortium
University of Maryland, Baltimore
Dana-Farber Cancer Institute
GlycoMimetics Incorporated
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
Stanford University
University of Ulm
National Cancer Institute (NCI)
University of Pittsburgh
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
University of Ulm
Fred Hutchinson Cancer Center